XPhyto Therapeutics (CSE: XPHY- OTCQB: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on what the company is planning for a very busy 2021. Rogers laying out the plan for three areas of their business.
Rogers telling Proactive they expect major steps forward in their Diagnostic, Drug Formulation, and Psychedelics divisions.
Price: 2.65 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
XPhyto Therapeutics (CSE: XPHY- OTCQB: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive with news the company has received the first purchases of their 25 minute rapid PCR test which is being manufactured in Germany. These tests will be used for regulatory approvals in a number...
Health
Industry & services
Health
Industry & services
Prev article
